Monopar Therapeutics
Clinical trials sponsored by Monopar Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a radioactive antibody light up hidden tumors on PET scans? Results expected Dec 2026 (estimated)
- Can a radioactive drug seek out and attack solid tumors? Results expected Jan 2027 (estimated)
-
Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?
Disease control Expanded access (paused)This program provides access to an investigational therapy called MNPR-101-PCTA-177Lu for people with advanced solid tumors that have not responded to existing treatments. The therapy combines an antibody with a radioactive payload, designed to bind to a protein called uPAR found…
Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a radioactive drug seek out and attack solid tumors?
Disease control OngoingThis early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a radioactive antibody light up hidden tumors on PET scans?
Diagnosis OngoingResearchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC